Biocept, Inc., an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms. It offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreatic biliary cancer, and ovarian cancer. The company sells its cancer diagnostic assays directly to oncologists and other physicians at private and group practices, hospitals, and cancer centers in the United States, as well as markets its clinical trial and research services to pharmaceutical and biopharmaceutical companies, and clinical research organizations. Biocept, Inc. was founded in 1997 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone858-320-8200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.25 million
Profitability
Miscellaneous
Employees95
Next Earnings Date8/13/2019 (Estimated)
OptionableOptionable
Biocept (NASDAQ:BIOC) Frequently Asked Questions
What is Biocept's stock symbol?
Biocept trades on the NASDAQ under the ticker symbol "BIOC."
How were Biocept's earnings last quarter?
Biocept Inc (NASDAQ:BIOC) announced its quarterly earnings data on Wednesday, May, 8th. The medical research company reported ($0.61) EPS for the quarter. The medical research company had revenue of $1.02 million for the quarter. Biocept had a negative return on equity of 338.61% and a negative net margin of 695.85%. View Biocept's Earnings History.
When is Biocept's next earnings date?
What price target have analysts set for BIOC?
2 analysts have issued 1-year price targets for Biocept's stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Biocept's share price to reach $3.00 in the next year. This suggests a possible upside of 130.8% from the stock's current price. View Analyst Price Targets for Biocept.
What is the consensus analysts' recommendation for Biocept?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biocept in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Biocept.
What are Wall Street analysts saying about Biocept stock?
Here are some recent quotes from research analysts about Biocept stock:
- 1. Maxim Group analysts commented, "Biocept reported 1Q19 with ~$1M in revenue and a net loss of $5.9M. The company ended the period with $14.8M in cash on the balance sheet." (5/9/2019)
- 2. According to Zacks Investment Research, "Biocept, Inc. is a commercial stage oncology diagnostics company. It has developed technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians. The company offers OncoCEE-BR (TM) test for breast cancer. Biocept, Inc. is headquartered in San Diego, California. " (2/13/2019)
Has Biocept been receiving favorable news coverage?
Headlines about BIOC stock have trended negative on Friday, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biocept earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave headlines about the medical research company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next several days.
Are investors shorting Biocept?
Biocept saw a decline in short interest during the month of April. As of April 30th, there was short interest totalling 823,156 shares, a decline of 34.1% from the April 15th total of 1,249,659 shares. Based on an average daily trading volume, of 734,933 shares, the days-to-cover ratio is presently 1.1 days. Approximately 4.5% of the shares of the stock are short sold. View Biocept's Current Options Chain.
Who are some of Biocept's key competitors?
What other stocks do shareholders of Biocept own?
Who are Biocept's key executives?
Biocept's management team includes the folowing people:
- Mr. Michael W. Nall, CEO, Pres & Director (Age 56)
- Mr. Timothy C. Kennedy, CFO, Sr. VP of Operations & Corp. Sec. (Age 61)
- Dr. Lyle J. Arnold, Sr. VP of R&D, Chief Scientific Officer and Member of Scientific Advisory Board (Age 72)
- Dr. Soon Kap Hahn Ph.D., Founder
- Mr. Pavel Tsinberg, Director of Technology Devel.
Who are Biocept's major shareholders?
Biocept's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.34%) and Northern Trust Corp (0.12%). View Institutional Ownership Trends for Biocept.
Which institutional investors are selling Biocept stock?
Which institutional investors are buying Biocept stock?
How do I buy shares of Biocept?
Shares of BIOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biocept's stock price today?
One share of BIOC stock can currently be purchased for approximately $1.30.
How big of a company is Biocept?
Biocept has a market capitalization of $24.53 million and generates $3.25 million in revenue each year. The medical research company earns $-24,570,000.00 in net income (profit) each year or ($9.01) on an earnings per share basis. Biocept employs 95 workers across the globe.
What is Biocept's official website?
How can I contact Biocept?
Biocept's mailing address is 5810 Nancy Ridge Drive, San Diego CA, 92121. The medical research company can be reached via phone at 858-320-8200 or via email at [email protected]
MarketBeat Community Rating for Biocept (NASDAQ BIOC)
MarketBeat's community ratings are surveys of what our community members think about Biocept and other stocks. Vote "Outperform" if you believe BIOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
